home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Leukaemia Halted in Mice

  August, 6 2000 9:24
your information resource in human molecular genetics

Designer molecules that destroy a type of leukaemia cell in culture have now been shown successfully to treat the malignant disease in mice. The 'ribozyme' kills these abnormal cells and prevents them from spreading by breaking a specific RNA link. This success raises the possibility of using it to treat human sufferers - perhaps by purging self-transplanted bone marrow of tumour cells.

In a Brief Communication this week (Nature, Vol. 406, Issue 6795, pp 473-474, August 3, 2000), Kazunari Taira of the University of Tokyo and colleagues describe how the ribozyme completely inhibits tumour-cell infiltration in mice with chronic myelogenous leukaemia (CML).

Two groups of mice were injected with CML cells with or without the ribozyme: those treated with cells not containing the designer molecule all died. The researchers dub their novel ribozyme a 'maxizyme'. When its two sensor arms identify the abnormal target RNA sequences, the molecule changes shape and forms a cavity that binds the magnesium needed to help break the bond. The CML cell then self-destructs.

Kazunari Taira
tel +81 3 5841 8828, fax +81 298 61 3019,
e-mail taira@chembio.t.u-tokyo.ac.jp

(C)Nature press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.